BREAST CANCER

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, describes the CELLSEARCH® CTC Test, which allows for an assessment of patient prognosis.

At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.

Debu Tripathy, MD, from the Norris Comprehensive Cancer Center, discusses the treatment of breast cancer with anthracyclines and trastuzumab.

Tamoxifen significantly lowered the risk of contralateral or secondary breast cancer by more than half in patients with BRCA1/2 mutations.

Max S. Wicha, MD, was part of the first team to discover stem cells in breast cancer, and he is among the most highly cited investigators in the field of cancer stem cells.

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses targeting the androgen receptor in breast cancer.

Jane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, discusses the ATM, CHEK2, and PTEN genes in breast cancer.

Hope S. Rugo, MD, from the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses pathway changes in breast cancer.

Sandra Swain, MD, medical director of the Washington Cancer Institute at MedStar Washington Hospital Center, gives an overview of the next steps for pertuzumab in breast cancer.

Torsten O. Nielsen, MD, PhD, FRCPC, professor, pathology, University of British Columbia, discusses Ki67 in breast cancer.

Richard Finn, MD, from UCLA, discusses the treatment of patients with estrogen receptor-positive (ER+) breast cancer with antiestrogens.

Antoni Ribas, MD, PhD, the director of the Tumor Immunology Program Area at UCLA's Jonsson Comprehensive Cancer Center, discusses PD-1 and PD-L1 in various cancers.

Women with breast cancer who were carriers of the BRCA1 mutation had increased mortality compared with noncarriers in preliminary results from a retrospective study.

Richard Finn, MD, from the Jonsson Comprehensive Cancer Center, UCLA, describes the development of cyclin-dependent kinases (CDKs) for the treatment of cancer.

Researchers at the NCI have developed the most comprehensive analysis of coding variants in the most frequently studied human tumor cell lines in cancer research.

High levels of HER2 expression in metastatic breast cancer tumors correlated with increased benefit from treatment with adotrastuzumab.

The next-generation PI3 kinase (PI3K) inhibitor GDC-0032 has shown signs of efficacy in patients with advanced cancers that were mutated for the PI3K alpha gene.

Emiel J. Rutgers, MD, from the Netherlands Cancer Institute, describes the personalization of treatment for patients with early-stage breast cancer.

If approved, this regimen would be the first neoadjuvant regimen ever approved for the treatment of cancer.

Jane E. Churpek, MD, describes the BROCA genetic assay, uses targeted genomic capture and next-generation sequencing to analyze a panel of 42 genes.

The mechanism of action of trastuzumab (Herceptin), a monoclonal antibody that is approved for the treatment of early-stage breast cancer that is HER2-positive.

Richard G. Gray, MA, MSc, discusses results from the randomized, phase III aTTom study that examined 10 years of tamoxifen versus the more standard 5 years.

Richard Finn, MD, comments on the future of palbociclib (PD 0332991), a novel oral selective inhibitor of cyclin-dependent kinase 4/6 (CDK 4/6), for the treatment of breast cancer.

Data from the French National Cancer Institute showed an increase in testing for BRCA1/2 for breast and ovarian cancer, though not for the MMR mutation for Lynch syndrome.

Andrew D. Seidman, MD, comments on the findings of the phase III S0221 trial, which compared two schedules of paclitaxel as adjuvant therapy for breast cancer.